Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More
FDA approves Lilly’s Omvoh: A breakthrough for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has sanctioned Eli Lilly and Company's Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), making it the pioneering ... Read More